UA82830C2 - Taci-immunoglobulin fused protein - Google Patents

Taci-immunoglobulin fused protein Download PDF

Info

Publication number
UA82830C2
UA82830C2 UA20031110605A UA20031110605A UA82830C2 UA 82830 C2 UA82830 C2 UA 82830C2 UA 20031110605 A UA20031110605 A UA 20031110605A UA 20031110605 A UA20031110605 A UA 20031110605A UA 82830 C2 UA82830 C2 UA 82830C2
Authority
UA
Ukraine
Prior art keywords
taci
immunoglobulin
amino acid
fragment
fusion protein
Prior art date
Application number
UA20031110605A
Other languages
English (en)
Ukrainian (uk)
Inventor
Jane A Gross
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of UA82830C2 publication Critical patent/UA82830C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
UA20031110605A 2001-05-24 2002-05-20 Taci-immunoglobulin fused protein UA82830C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29334301P 2001-05-24 2001-05-24
PCT/US2002/015910 WO2002094852A2 (en) 2001-05-24 2002-05-20 Taci-immunoglobulin fusion proteins

Publications (1)

Publication Number Publication Date
UA82830C2 true UA82830C2 (en) 2008-05-26

Family

ID=23128690

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20031110605A UA82830C2 (en) 2001-05-24 2002-05-20 Taci-immunoglobulin fused protein

Country Status (27)

Country Link
US (9) US20030103986A1 (de)
EP (2) EP2116259B1 (de)
JP (2) JP2004535182A (de)
KR (3) KR101021124B1 (de)
CN (2) CN101628111B (de)
AT (2) ATE446771T1 (de)
AU (1) AU2002305646C1 (de)
BR (1) BRPI0209933B8 (de)
CA (1) CA2448123C (de)
CY (2) CY1109751T1 (de)
DE (1) DE60234202D1 (de)
DK (2) DK2116259T3 (de)
EA (2) EA007275B1 (de)
ES (2) ES2379977T3 (de)
HR (2) HRP20130413A2 (de)
IL (2) IL158920A0 (de)
ME (1) MEP21708A (de)
MX (1) MXPA03010687A (de)
NO (1) NO337295B1 (de)
NZ (1) NZ529638A (de)
PL (2) PL219013B1 (de)
PT (2) PT1436003E (de)
RS (2) RS20120253A1 (de)
SI (2) SI1436003T1 (de)
UA (1) UA82830C2 (de)
WO (1) WO2002094852A2 (de)
ZA (1) ZA200308984B (de)

Families Citing this family (210)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US6969519B2 (en) 2000-03-10 2005-11-29 Human Genome Sciences, Inc. Methods of using an agonistic antibody human tumor necrosis factor receptor (TR17)
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
KR20120053525A (ko) * 2000-06-16 2012-05-25 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
WO2002016411A2 (en) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EP2270040A3 (de) 2000-08-18 2011-07-06 Human Genome Sciences, Inc. Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
IL160127A0 (en) * 2001-08-03 2004-06-20 Genentech Inc Tacis and br3 polypeptides and uses thereof
US7112410B1 (en) 2001-08-29 2006-09-26 Human Genome Sciences, Inc. Human tumor necrosis factor TR21 and methods based thereon
US7256015B2 (en) * 2001-09-21 2007-08-14 Amgen Inc. TALL-1 receptor molecules and uses thereof
US20040018573A1 (en) * 2002-04-18 2004-01-29 Power Scott D Production of functional antibodies in filamentous fungi
AU2003267967B2 (en) * 2002-06-18 2008-11-20 Zymogenetics, Inc. Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
AU2003284260B2 (en) * 2002-10-11 2010-06-03 Zymogenetics, Inc. Production of homotrimeric fusion proteins
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
ATE517914T1 (de) 2004-03-08 2011-08-15 Zymogenetics Inc Dimere fusionsproteine und materialien und verfahren zu deren herstellung
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
EP3489257A1 (de) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii-rezeptor-polypeptide, verfahren und zusammensetzungen
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1791565B1 (de) 2004-09-23 2016-04-20 Genentech, Inc. Zystein-modifizierte Antikörper und Konjugate
ATE450615T1 (de) 2005-07-22 2009-12-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
EP1922080A2 (de) * 2005-08-09 2008-05-21 ZymoGenetics, Inc. Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
US8808696B2 (en) 2005-08-09 2014-08-19 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US20090226440A1 (en) * 2005-08-12 2009-09-10 Shane Grey Prophylactic and/or Therapeutic Method for Treatment of Autoimmune Disease
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
PT1973559E (pt) 2005-11-23 2013-02-19 Acceleron Pharma Inc Antagonistas de activina-actriia e utilizações para promover o crescimento ósseo
AU2007235212A1 (en) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Truncated IL-17RA soluble receptor and methods of using in inflammation
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (pt) 2006-05-15 2012-01-17 Ares Trading Sa métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
CA2661936A1 (en) * 2006-08-25 2008-02-28 Margaret D. Moore Soluble il-27 receptor
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
CN101535335B (zh) * 2006-08-28 2013-10-02 阿雷斯贸易股份有限公司 含Fc-蛋白的纯化方法
KR101770312B1 (ko) * 2006-08-28 2017-08-22 아레스 트레이딩 에스.에이. Ｆｃ­함유 단백질을 정제하는 방법
JP2010501622A (ja) * 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
WO2009019531A2 (en) 2006-09-18 2009-02-12 Compugen Ltd Bioactive peptides and method of using same
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100063257A1 (en) * 2007-01-26 2010-03-11 Merck Serono Sa Purification of FC-TACI Fusion Proteins Using the Oilbody Technology
TWI584815B (zh) 2007-02-01 2017-06-01 艾瑟勒朗法瑪公司 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
RS52888B (sr) 2007-03-27 2014-02-28 Zymogenetics Inc. Kombinacija blys inhibicije i mikofenolat mofetila za lečenje autoimunog obolenja
AU2008232311A1 (en) * 2007-03-27 2008-10-02 Niall Corcoran Methods and compositions for treating prostate cancer
CN101323643B (zh) * 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
HRP20150512T1 (hr) 2007-09-04 2015-06-19 Compugen Ltd. Polipeptidi i polinukleotidi, te njihova uporaba kao ciljnih molekula za proizvodnju lijekova i bioloških sredstava
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
ES2565202T3 (es) * 2007-10-16 2016-04-01 Zymogenetics, Inc. Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
PT2219675E (pt) 2007-11-12 2013-11-18 Ares Trading Sa Formulações para proteínas de fusão de taci-imunoglobulina
WO2009062916A1 (en) * 2007-11-12 2009-05-22 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of optic neuritis
CA2705435A1 (en) * 2007-11-12 2009-05-22 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of relapsing multiple sclerosis
EP2217268B1 (de) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Monoklonale antii-human-il-21-antikörper
EP2240196A2 (de) * 2008-01-22 2010-10-20 Compugen Ltd. Peptide aus clusterin
WO2009132058A2 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
HUE028784T2 (en) * 2008-05-01 2017-01-30 Zymogenetics Inc Serum levels and use of BLYS / APRIL heterotrimers in diagnostic procedures
JP2011526154A (ja) 2008-06-27 2011-10-06 ザイモジェネティクス， インコーポレイテッド 可溶性ハイブリッドＦｃγレセプターおよび関連する方法
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2343080B1 (de) * 2008-09-30 2017-11-08 Kyowa Hakko Kirin Co., Ltd. PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON KNOCHENERKRANKUNGEN MIT EINEM PROTEIN MIT EXTRAZELLULÄREN ZYSTEINREICHEN FRIZZLED1-, FRIZZLED2- ODER FRIZZLED7-DOMÄNEN UND Fc PROTEIN
US20110311450A1 (en) 2008-12-08 2011-12-22 Zurit Levine Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
WO2010096394A2 (en) * 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP3058986B1 (de) 2009-03-30 2018-05-09 Acceleron Pharma Inc. Bmp-alk3-antagonisten und ihre verwendung zur förderung des knochenwachstums
MX355042B (es) 2009-06-08 2018-04-02 Acceleon Pharma Inc Metodos para aumentar adipositos termogenicos.
CN102656187A (zh) 2009-06-12 2012-09-05 阿塞勒隆制药公司 截短的actriib-fc融合蛋白
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
WO2011102845A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Rage fusion protein compositions and methods of use
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
PH12012501836A1 (en) 2010-04-15 2013-02-04 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
KR101839163B1 (ko) 2010-06-08 2018-03-15 제넨테크, 인크. 시스테인 조작된 항체 및 접합체
BR112012031329A2 (pt) 2010-06-09 2016-10-11 Zymogenetics Inc proteínas de fusão diméricas vstm3 e composições e métodos relacionados
EP3327035A1 (de) 2010-06-22 2018-05-30 Precision Biologics Inc. Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
US20130209463A1 (en) 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
US9068014B2 (en) 2010-09-23 2015-06-30 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
WO2012071554A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
WO2012090150A2 (en) 2010-12-27 2012-07-05 Compugen Ltd New cell-penetrating peptides and uses thereof
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
CN102085367B (zh) * 2011-01-19 2012-08-22 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗类风湿性关节炎药物的应用
NZ713461A (en) 2011-04-15 2017-02-24 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
WO2012160448A2 (en) 2011-05-25 2012-11-29 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory disorders
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EA026827B1 (ru) 2011-10-14 2017-05-31 Медимьюн Лимитед Пирролбензодиазепины и их конъюгаты
EP2780033B1 (de) 2011-11-14 2019-05-08 Five Prime Therapeutics, Inc. Eine fgfr1 extrazelluläre domäne zur behandlung von krebs mit einer fgfr1 gen vervielfältigung
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
FI3421486T3 (fi) 2012-06-22 2023-12-15 Dartmouth College Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
EP2892558B1 (de) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista-modulatoren zur diagnose und behandlung von krebs
HUE042731T2 (hu) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
LT2906296T (lt) 2012-10-12 2018-06-11 Adc Therapeutics Sa Pirolobenzodiazepino-antikūno konjugatai
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
RS56520B1 (sr) 2012-10-12 2018-02-28 Adc Therapeutics Sa Pirolobenzodiazepin-anti-cd22 konjugati antitela
EP2914277B1 (de) 2012-11-02 2017-09-13 Celgene Corporation Activin-actrii-antagonisten und verwendungen zur behandlung von knochen- und anderen erkrankungen
CN103833856B (zh) * 2012-11-22 2017-05-03 上海康岱生物医药技术股份有限公司 抑制taci‑baff复合物形成的融合蛋白及其制法和用途
EP2935273A1 (de) 2012-12-21 2015-10-28 MedImmune Limited Asymmetrische pyrrolobenzodiazepin-dimere zur verwendung bei der behandlung von proliferativen und autoimmunerkrankungen
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
KR102066319B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
EP3033111B1 (de) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chlormethyl) 2,3-dihydro-1h-benzo[e]indoldimer-antikörper-wirkstoff-konjugatverbindungen und verfahren zur verwendung und behandlung
EP3054986B1 (de) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
SG11201604905WA (en) 2013-12-16 2016-07-28 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof
KR102354207B1 (ko) 2013-12-16 2022-01-20 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
CN114163529B (zh) 2013-12-24 2024-12-13 杨森制药公司 抗vista抗体及片段
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
CN114699529A (zh) 2014-06-13 2022-07-05 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
US20170275344A1 (en) 2014-08-26 2017-09-28 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
CA2957354A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP3212787B1 (de) 2014-10-28 2019-07-10 Merck Patent GmbH Verfahren zur anzeige von nichtkovalenten fc-domain-haltigen proteinen auf der oberfläche von zellen und verfahren zum screening davon
JP6734271B2 (ja) 2014-11-03 2020-08-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 二重特異性サメ抗体可変ドメインの製造方法およびそれらの使用
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
AU2016306907A1 (en) 2015-08-07 2018-03-29 Merck Patent Gmbh A transglutamine tag for efficient site-specific bioconjugation
EP3328881B1 (de) 2015-09-08 2019-08-28 Theripion, Inc. Apoa-1-fusionspolypeptide sowie zugehörige zusammensetzungen und verfahren
AU2016331931C1 (en) 2015-10-02 2020-01-16 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
JP6621919B2 (ja) 2015-10-16 2019-12-18 ジェネンテック， インコーポレイテッド 束縛ジスルフィド薬物コンジュゲート
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック， インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CN121431692A (zh) 2016-03-25 2026-01-30 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
AU2017250294B2 (en) 2016-04-15 2022-07-21 Immunext Inc. Anti-human VISTA antibodies and use thereof
CN109311977B (zh) 2016-04-15 2022-06-14 H.伦德贝克公司 人源化的抗pacap抗体及其用途
CA3019398A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3458101B1 (de) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac-antikörper-konjugate und verfahren zur verwendung
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック， インコーポレイテッド シルベストロール抗体－薬物コンジュゲート及び使用方法
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018136163A2 (en) 2016-12-09 2018-07-26 Theripion, Inc. Tandem apoa-1 fusion polypeptides
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HRP20210979T1 (hr) 2017-02-08 2021-09-17 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protutijelo
PT3612537T (pt) 2017-04-18 2022-08-29 Medimmune Ltd Conjugados de pirrolobenzodiazepina
MX2019012464A (es) 2017-04-20 2019-12-11 Adc Therapeutics Sa Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl.
KR102755136B1 (ko) 2017-05-09 2025-01-17 심리스 바이오로직스 게엠베하 변형된 마이크로시스틴 및 노둘라린
WO2018219619A1 (en) 2017-05-09 2018-12-06 Cyano Biotech Gmbh Method for modifying microcystins and nodularins
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
SMT202200225T1 (it) 2017-08-18 2022-07-21 Medimmune Ltd Coniugati di pirrolobenzodiazepina
US11517591B2 (en) * 2017-09-01 2022-12-06 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. ANALOGUES OF THAILANSTATINE
CN111868082A (zh) 2018-02-02 2020-10-30 博奥泰克尼公司 调节vista和vsig3的相互作用的化合物及其制备和使用方法
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
IL282441B2 (en) 2018-10-24 2025-07-01 Hoffmann La Roche Conjugated chemical inducers of degradation and methods of use
JP2022513198A (ja) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP3938372B1 (de) 2019-03-15 2023-10-25 MedImmune Limited Azetidobenzodiazepindimere und konjugate damit zur verwendung in der behandlung von krebs
EP4004044A1 (de) 2019-07-24 2022-06-01 H. Lundbeck A/S Anti-mglur5-antikörper und verwendungen davon
EP3868403A4 (de) * 2019-12-24 2022-04-06 RemeGen Co., Ltd. Taci-fc-fusionsprotein und verwendung davon
MX2022013998A (es) 2020-05-08 2023-02-16 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff con y sin una proteina inhibidora de celulas t y metodos de uso de las mismas.
IL298643A (en) * 2020-06-02 2023-01-01 Ares Trading Sa Methods related to the treatment of iga nephropathy
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022178078A1 (en) 2021-02-19 2022-08-25 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods
US20240270842A1 (en) 2021-05-07 2024-08-15 Viela Bio, Inc Use of an anti-cd19 antibody to treat myasthenia gravis
AU2022269139A1 (en) 2021-05-07 2023-11-16 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
TW202323304A (zh) * 2021-09-30 2023-06-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ２３抗體融合蛋白及用途
AU2022358137B2 (en) * 2021-09-30 2026-02-12 Remegen Co., Ltd. Method for treating sjogren’s syndrome using taci-fc fusion protein
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
WO2023236967A1 (zh) * 2022-06-08 2023-12-14 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗重症肌无力的方法
CN119698304A (zh) * 2022-09-30 2025-03-25 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗膜性肾病的方法
CN120344256A (zh) 2022-10-04 2025-07-18 高山免疫科学股份有限公司 突变的taci-fc融合蛋白用于在治疗自身抗体介导的疾病中的用途
WO2024114777A1 (zh) * 2022-12-02 2024-06-06 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗微小病变型肾病的方法
EP4630445A2 (de) * 2022-12-05 2025-10-15 Alexion Pharmaceuticals, Inc. Taci-fc-fusionsproteine zur multifunktionellen hemmung von baff, april und neonatalem fc-rezeptor
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
EP4683948A1 (de) 2023-03-21 2026-01-28 Biograph 55, Inc. Multispezifische cd19/cd38-antikörper
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2024259220A1 (en) 2023-06-15 2024-12-19 Theripion, Inc. Pon3 and evolved pon1 fusion polypeptides
CN121152636A (zh) * 2023-07-06 2025-12-16 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗ANCA相关性血管炎的方法
WO2025209465A1 (zh) * 2024-04-02 2025-10-09 福佑泰生物制药公司 Taci/bcma嵌合体融合蛋白及其用途
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738A (en) 1848-08-29 Francis kelsey
US846A (en) 1838-07-17 Improvement in revolving fire-arms
DK368882A (da) 1981-08-25 1983-02-26 Alan John Kingsman Expessions vektorer
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4990446A (en) 1984-12-06 1991-02-05 Labofina, S.A. Promoters for the expression of foreign genes in yeast, plasmids comprising them, and use thereof for the production of polypeptides
US4751181A (en) 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5861151A (en) * 1991-12-20 1999-01-19 Bristol-Myers Squibb Co Soluble fusion molecules with binding specificity for cell adhesion molecules
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ZA932523B (en) * 1992-04-10 1994-10-08 Res Dev Foundation Immunotoxins directed against cd33 related surface antigens
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
US5650550A (en) 1993-10-01 1997-07-22 The United States Of America As Represented By The Department Of Health And Human Services Mutant mice having a deficit of functional estrogen receptors
US5523227A (en) 1994-06-17 1996-06-04 The Board Of Trustees Of The Leland Stanford Junior Univ. DNA encoding calcium-signal modulating cyclophilin ligand
CA2207815C (en) 1994-12-15 2011-03-29 Yeda Research And Development Co., Ltd. Modulators of the function of fas/apo1 receptors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19533447C1 (de) 1995-09-09 1996-12-05 Bbs Kraftfahrzeugtechnik Verfahren und Vorrichtung zum Befüllen eines Gießwerkzeugs mit einer Metallschmelze
WO1997017451A2 (en) 1995-11-09 1997-05-15 Zymogenetics, Inc. Production of gad65 in methylotrophic yeast
US5716808A (en) 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
CN1214050A (zh) 1996-03-14 1999-04-14 人体基因组科学有限公司 人肿瘤坏死因子δ和ε
AU708572B2 (en) 1996-07-17 1999-08-05 Zymogenetics Inc. Preparation of (pichia methanolica) auxotrophic mutants
CA2261151C (en) 1996-07-17 2003-09-16 Zymogenetics, Inc. Transformation of pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
IL132249A0 (en) * 1997-04-18 2001-03-19 Biogen Inc Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
JP2002517977A (ja) 1997-06-06 2002-06-18 リジェネロン ファーマシューティカルズ，インコーポレイテッド Ｔｎｆリガンドファミリーのｎｔｎ−２メンバー
WO1998055620A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
AU9013998A (en) * 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
HUP0004611A3 (en) 1997-09-12 2002-04-29 Apotech R & D Sa April- a novel protein with growth effects
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
ATE437227T1 (de) 1999-01-07 2009-08-15 Zymogenetics Inc Verfahren zur therapeutischen verwendung von löslichen rezeptoren br43x2
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
PL198934B1 (pl) 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
WO2000062790A2 (en) 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1806143B1 (de) 1999-08-17 2016-06-15 Biogen MA Inc. BAFF-Rezeptor (BCMA), ein immunregulatorischer Wirkstoff
AU7602400A (en) * 1999-09-20 2001-04-24 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
ATE511857T1 (de) 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
AU5392001A (en) * 2000-04-27 2001-11-07 Biogen Inc Taci as an anti-tumor agent
WO2001087979A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2002014504A1 (en) 2000-08-11 2002-02-21 Kirin Beer Kabushiki Kaisha Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
WO2002038766A2 (en) 2000-11-07 2002-05-16 Zymogenetics, Inc. Human tumor necrosis factor receptor
AU2002238052A1 (en) * 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
PT2219675E (pt) 2007-11-12 2013-11-18 Ares Trading Sa Formulações para proteínas de fusão de taci-imunoglobulina

Also Published As

Publication number Publication date
EA007275B1 (ru) 2006-08-25
US20090209006A1 (en) 2009-08-20
EA200301146A3 (ru) 2005-02-24
HK1137659A1 (en) 2010-08-06
EP1436003A4 (de) 2005-04-27
EA200301146A2 (ru) 2004-06-24
YU92503A (sh) 2006-05-25
US7964711B2 (en) 2011-06-21
DE60234202D1 (de) 2009-12-10
US20100130728A1 (en) 2010-05-27
ES2334772T3 (es) 2010-03-16
MEP21708A (en) 2010-06-10
HRP20030948A2 (en) 2004-06-30
JP2004535182A (ja) 2004-11-25
PL366760A1 (en) 2005-02-07
US20100129384A1 (en) 2010-05-27
KR100976743B1 (ko) 2010-08-19
BRPI0209933B8 (pt) 2021-05-25
IL158920A0 (en) 2004-05-12
ES2334772T7 (es) 2012-11-19
US20030103986A1 (en) 2003-06-05
CN101628111A (zh) 2010-01-20
US8524232B2 (en) 2013-09-03
US20140328844A1 (en) 2014-11-06
EP1436003A2 (de) 2004-07-14
IL217265A (en) 2013-05-30
JP5149245B2 (ja) 2013-02-20
BR0209933A (pt) 2004-03-30
ES2379977T3 (es) 2012-05-07
IL217265A0 (en) 2012-02-29
SI2116259T1 (sl) 2012-11-30
PL403488A1 (pl) 2013-07-08
US7862814B2 (en) 2011-01-04
DK1436003T3 (da) 2010-03-15
HRP20030948B1 (hr) 2013-06-30
CY1109751T1 (el) 2014-09-10
WO2002094852A8 (en) 2004-04-22
KR20090080570A (ko) 2009-07-24
NZ529638A (en) 2007-08-31
NO20035173D0 (no) 2003-11-21
CN1612750B (zh) 2012-10-31
EP2116259B1 (de) 2012-01-25
CY1112840T1 (el) 2016-02-10
US20130309231A1 (en) 2013-11-21
US20110229473A1 (en) 2011-09-22
US9346878B2 (en) 2016-05-24
BRPI0209933B1 (pt) 2018-10-16
KR20100061860A (ko) 2010-06-09
RS20120253A1 (sr) 2013-02-28
PT2116259E (pt) 2012-04-09
MXPA03010687A (es) 2004-07-01
KR101021124B1 (ko) 2011-03-14
SI1436003T1 (sl) 2010-02-26
US20100183609A1 (en) 2010-07-22
US7635767B2 (en) 2009-12-22
HK1076603A1 (en) 2006-01-20
ATE446771T1 (de) 2009-11-15
EP1436003B3 (de) 2012-03-14
US7951919B2 (en) 2011-05-31
KR20040030628A (ko) 2004-04-09
AU2002305646C1 (en) 2009-08-06
US20060034852A1 (en) 2006-02-16
CA2448123A1 (en) 2002-11-28
JP2009232856A (ja) 2009-10-15
AU2002305646B2 (en) 2008-09-04
CN101628111B (zh) 2013-11-06
EA010594B1 (ru) 2008-10-30
NO20035173L (no) 2004-01-23
WO2002094852A2 (en) 2002-11-28
HRP20130413A2 (hr) 2013-07-31
US7501497B2 (en) 2009-03-10
ZA200308984B (en) 2004-07-20
RS52228B (sr) 2012-10-31
CA2448123C (en) 2012-09-11
PL219013B1 (pl) 2015-02-27
US8815238B2 (en) 2014-08-26
CN1612750A (zh) 2005-05-04
ATE542545T1 (de) 2012-02-15
EP1436003B1 (de) 2009-10-28
EA200600894A1 (ru) 2007-08-31
NO337295B1 (no) 2016-03-07
DK2116259T3 (da) 2012-05-21
EP2116259A1 (de) 2009-11-11
PT1436003E (pt) 2010-03-12

Similar Documents

Publication Publication Date Title
UA82830C2 (en) Taci-immunoglobulin fused protein
US20250304930A1 (en) Expression of novel cell tags
JP7134204B2 (ja) キメラ受容体及びその使用方法
AU2020203836B2 (en) Anti-CD70-chimeric antigen receptors
JP7352473B2 (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
JP5904985B2 (ja) 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
EA009026B1 (ru) Антитела против il-22ra, их партнеры по связыванию и способы их применения при воспалениях
UA126441C2 (uk) Химерні антигенні рецептори, націлені на bcma, та способи їх застосування
UA129833C2 (uk) Гібридний білок, що містить поліпептид варіантного ліганду icos
JP6761113B2 (ja) キメラ抗原受容体
CN112469829A (zh) 包含抗gpc3单链抗体的car
CA3026180A1 (en) Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
UA118950C2 (uk) Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
EA030313B1 (ru) СПОСОБ СНИЖЕНИЯ УРОВНЕЙ IgM, IgG И IgA У МЛЕКОПИТАЮЩИХ И КОМПОЗИЦИЯ ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА
JP2020505069A (ja) ＴＧＦ−βデコイ受容体
US11834516B2 (en) Tumor-specific polypeptide and use thereof
EA015706B1 (ru) Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
CN113621077B (zh) 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
CN112533629A (zh) 结合使用il-10药剂与嵌合抗原受体细胞疗法的组合物和方法
JP2023510870A (ja) Ｉｃｄ ｓｔａｔシグナル伝達が改変されたｃｄ１２２
EP3786178A1 (de) Für ebv-abgeleitete antigene spezifische tcr-konstrukte
JP2000502569A (ja) Ｏｂタンパク質レセプター及び関連組成物と関連方法
US8404803B2 (en) Cancer-associated antigen analogue peptides and uses thereof
US20090162374A1 (en) Specific removal of activated immune cells
US20090081221A1 (en) Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method